Klotho

Mechanism of action

Klotho is a single-pass transmembrane glycoprotein encoded by the KL gene, discovered by Makoto Kuro-o and colleagues in 1997 through the striking observation that homozygous KL gene mutation in mice produces a dramatic accelerated-ageing phenotype resembling human progeria — with substantially shortened lifespan, arteriosclerosis, skin atrophy, osteoporosis, pulmonary emphysema, and impaired reproduction. The gene was named for Klotho, the Greek Fate who spins the thread of life at birth, reflecting its established role as a foundational longevity gene. The remarkable severity of the Klotho-knockout phenotype established Klotho as one of the most-validated longevity-related genetic targets in mammalian biology. The molecular functions of Klotho have proven complex and multi-faceted. The best-characterised mechanism involves function as the essential co-receptor for fibroblast growth factor 23 (FGF23) — a bone-derived hormone regulating phosphate homeostasis. FGF23 binds to FGF receptors (particularly FGFR1c) in association with Klotho on renal tubular cells, driving renal phosphate excretion and vitamin D metabolism modulation. Klotho-knockout mice therefore have profoundly disrupted phosphate homeostasis and vitamin D metabolism, contributing substantially to the accelerated-ageing phenotype. This FGF23-co-receptor function is the primary Klotho mechanism from a phosphate-and-mineral-metabolism standpoint. A proteolytically cleaved soluble ~65-70 kDa extracellular domain of Klotho circulates in plasma and appears to have additional independent effects distinct from the FGF23-co-receptor function. Soluble Klotho affects IGF-1 signalling through modulation of insulin/IGF-1 receptor signalling on target cells, modestly attenuating chronic supraphysiological IGF-1 signalling in a manner that may contribute to longevity effects (paralleling the caloric-restriction-and-IGF-1-signalling framework). Soluble Klotho additionally modulates transient receptor potential (TRP) channels affecting calcium homeostasis, and provides antioxidant effects potentially through direct scavenging or indirect FoxO-transcription-factor modulation. In the central nervous system, Klotho expression in choroid plexus and various neurons produces neuroprotective effects including improved synaptic plasticity, enhanced cognitive function in aged animals, and protection against neurodegenerative disease models. Soluble Klotho administration in aged mice has produced cognitive improvements documented across multiple laboratories. The pharmacological space for Klotho intervention includes: recombinant soluble Klotho protein administration (pre-clinical exploration); Klotho gene therapy through viral vector delivery (pre-clinical); and small-molecule Klotho activators that upregulate endogenous Klotho expression (early research). Clinical development has been limited to date, though the strength of the pre-clinical evidence and the exceptional validation of Klotho as a longevity gene continues to drive research investment. A notable clinical observation supporting Klotho's human longevity relevance: human genetic variants in KL are associated with lifespan differences in some studies, and human centenarians and long-lived individuals have been reported to have elevated circulating Klotho levels compared to age-matched shorter-lived controls. These human observations are less definitive than the mouse-model data but consistent with the Klotho-longevity framework.

Klotho was named after the Greek Fate who spins the thread of life at birth, reflecting the dramatic accelerated-ageing phenotype produced by loss-of-function in mice (Kuro-o et al., Nature 1997). Transgenic Klotho overexpression extends mouse lifespan by 20-30%. Human centenarians have elevated Klotho versus age-matched shorter-lived controls. These observations establish Klotho as one of the most-validated longevity gene targets in mammalian biology, though clinical translation to human therapy has been limited to date.

— Notable finding

Research history

Klotho was discovered by Makoto Kuro-o and colleagues at the National Institute of Neuroscience in Tokyo through characterisation of a mouse line carrying a spontaneous insertion mutation that produced accelerated-ageing phenotype. The seminal Nature paper (Kuro-o et al., Nature 1997) characterised the affected gene and named it Klotho, establishing the compound as a foundational longevity-gene target. The immediate impact on the aging research field was substantial — the dramatic phenotype produced by loss of a single gene product provided a compelling example of longevity gene function. Subsequent research across the 2000s and 2010s characterised the multiple functions of Klotho including the FGF23-co-receptor role, the soluble Klotho circulating fragment, and the various tissue-specific effects on kidney, cardiovascular, central nervous system, and other systems. Overexpression studies produced the mirror-image finding to the knockout: transgenic mice overexpressing Klotho live approximately 20-30% longer than wild-type controls, with improved healthspan markers. Human research has documented age-related decline in circulating soluble Klotho levels, associations between Klotho variants and human lifespan in some studies, and elevated Klotho in centenarians. These human observations are less definitive than the mouse-model data but consistent with the longevity framework. Clinical development has been limited. Some biotech programmes have explored Klotho protein administration and Klotho gene therapy approaches; others have explored small-molecule Klotho activators. As of 2026 no Klotho-based therapy has achieved marketing authorisation, though research investment continues. Klotho protein and Klotho-related research reagents are available from research suppliers for legitimate laboratory research. The relatively large protein size (~65-130 kDa depending on form) and the complex production requirements make Klotho research reagents less widely commoditised than smaller peptide products.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Klotho safety data derive primarily from pre-clinical work in rodent models. The pre-clinical safety record has been favourable at research doses — no overt toxicity, no significant changes in routine haematology or hepatic enzymes, no organ-specific lesions in standard histopathology. As an endogenous protein whose overexpression extends lifespan in transgenic mice and whose loss produces accelerated aging, the safety framework of Klotho supplementation is theoretically favourable — the intervention is essentially normalising or elevating an endogenous protein whose age-related decline contributes to aging. Recombinant α-Klotho protein administered systemically to aged rodents has not produced adverse phenotypes in the studies published to date and has consistently reversed rather than induced age-related biomarker deterioration. Theoretical safety concerns include: modulation of phosphate and mineral metabolism through the FGF23-co-receptor function (over-correction of physiological phosphate handling could theoretically produce hypophosphataemia, particularly relevant in chronic kidney disease populations where FGF23-Klotho axis dysregulation is already established); modulation of IGF-1 signalling with potential effects on growth and metabolism; complex effects on the FGF/FGFR signalling network that includes FGFR-mediated tumour-growth mechanisms; and the possibility that chronic supraphysiological soluble Klotho exposure produces effects distinct from restoring youthful physiological levels. Immunogenicity considerations are relevant given the large (~65-130 kDa) protein size — extended recombinant-Klotho administration could plausibly elicit anti-drug antibodies with unknown pharmacological or safety consequences. The absence of large-scale clinical trial data means antibody-response profiles are essentially uncharacterised. Clinical safety data are limited given the absence of large-scale clinical trials. Human use of Klotho preparations without proper clinical characterisation carries substantial uncertainty; the compound remains a research reagent rather than a therapy candidate outside carefully controlled early-clinical programmes.

UK regulatory status

Klotho (recombinant α-Klotho or soluble Klotho protein) is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971 and does not fall within any specific UK controlled-substance framework. Research-grade material is available from biochemistry-reagent and research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply for human use engages the Human Medicines Regulations 2012 — supplying, offering to supply, or advertising for supply of an unauthorised medicine to a member of the public are the specific offences that most commonly arise. Enforcement in this space has been limited given the relatively small research-chemical market share of Klotho compared to more visible peptides. Advertising Klotho preparations for longevity, anti-aging, or any therapeutic claim to UK consumers engages Advertising Standards Authority (ASA) jurisdiction in addition to MHRA enforcement over unlicensed-medicine promotion. Longevity biotech promotional material referring to Klotho requires careful framing to avoid ASA action. Klotho is not currently on the WADA Prohibited List. Its complex multi-function pharmacology does not fall within any current WADA category, though athletes should verify the current annual Prohibited List and note that unlicensed peptides carry inherent contamination-risk under the strict-liability anti-doping framework. For animal research under the Animals (Scientific Procedures) Act 1986 (ASPA), Klotho work in vertebrates requires standard project and personal licences.

Frequently asked questions